评估需求

[{"query":"请评估","message_files":[{"url":"https://ai.medsci.cn/dev-api/admin-api/infra/file/4/get/b69e326d7821e2cd37d41a2a1a0354016c36eb0b62483a41cbfd78a2daae6eef.docx","type":"document","size":20763,"filename":"temp213973287778360070_虚拟临床研究案例2.docx"}],"answer":"\n\n提炼待评估文件信息：\n\n题目： \nLong-term survival, recurrence, and secondary event patterns after 25 years in a randomized trial of adjuvant letrozole versus tamoxifen in postmenopausal women with early-stage breast cancer \n\n摘要： \n该研究报告了CALIBER试验的25年随访结果，比较了绝经后ER阳性早期乳腺癌患者接受5年芳香化酶抑制剂（letrozole）与他莫昔芬（tamoxifen）治疗的长期效果。主要发现包括： \n1. 总体生存率在两组间无显著差异。 \n2. letrozole在前10年显示出无病生存优势，但此效应在10年后减弱。 \n3. letrozole显著降低了对侧乳腺癌和子宫内膜癌的终生风险，但增加了骨折和心血管事件的风险。 \n\n研究目标： \n评估letrozole与tamoxifen在长期随访中的总体生存率、疾病复发率及次要事件（如骨折、心血管事件、对侧乳腺癌和子宫内膜癌）的发生率。 \n\n研究方法： \n- 设计：CALIBER试验为前瞻性、随机、双盲研究。 \n- 样本：5188名绝经后ER阳性乳腺癌患者。 \n- 随访时间：中位随访时间为24.8年。 \n- 主要终点：总体生存率。 \n- 次要终点：无病生存率、对侧乳腺癌、子宫内膜癌、骨折和心血管事件的发生率。 \n\n主要结果： \n1. 总体生存率： 两组间无显著差异（HR 0.94, p=0.23）。 \n2. 无病生存率： letrozole在前10年显示优势（HR 0.86, p=0.007），但10年后无显著差异。 \n3. 对侧乳腺癌： letrozole组风险显著降低（HR 0.79, p=0.018）。 \n4. 子宫内膜癌： letrozole组风险显著降低（HR 0.31, p<0.001）。 \n5. 骨折： letrozole组风险显著增加（HR 1.38, p<0.001）。 \n6. 心血管事件： letrozole组风险略有增加（HR 1.15, p=0.035）。 \n\n讨论： \n研究表明，letrozole和tamoxifen在25年随访中总体生存率相似，但在次要事件上存在显著差异。letrozole在降低对侧乳腺癌和子宫内膜癌风险方面具有优势，但需权衡骨折和心血管事件的风险。 \n\n预期目标： \n该研究旨在为乳腺癌患者的个性化治疗决策提供长期随访数据支持。\n\n---\n\n综上所述，需求分类为“文章审稿”。\n\n分类科学家判断您的研究类型为：临床研究\n\n临床研究专家正在审核中~\n\n### 评估过程\n\n#### 1. 研究设计\n- 前瞻性、随机、双盲研究：该研究设计确保了结果的可靠性和可比性。通过随机分配患者到不同的治疗组，可以减少选择偏差，并通过双盲方式避免了偏见。\n- 样本量：研究纳入了5188名绝经后ER阳性早期乳腺癌患者，样本量较大，能够提供有力的数据支持。\n- 随访时间：中位随访时间为24.8年，长达25年的随访提供了长期疗效和安全性数据，有助于全面了解不同治疗方法的长期影响。\n\n#### 2. 研究目的\n- 总体生存率：研究的主要目的是评估两种治疗方法在长期随访中的总体生存率，这直接关系到患者的长期预后。\n- 疾病复发率：次要终点之一是评估无病生存率，这对于理解治疗的效果至关重要。\n- 次要事件：还包括评估骨折、心血管事件、对侧乳腺癌和子宫内膜癌等次要事件的发生率，这些信息对于指导个体化治疗决策非常重要。\n\n#### 3. 数据收集与分析\n- 数据来源：通过国家健康注册库和患者记录链接获取数据，确保了数据的准确性和完整性。\n- 统计方法：采用意向治疗人群进行分析，使用Kaplan-Meier方法和log-rank检验来评估生存率，使用Cox比例风险模型计算危险比（HR）和置信区间（CI），这些方法都是标准且可靠的统计手段。\n- 分层分析：根据淋巴结状态和既往化疗使用情况进行了分层分析，提高了结果的精确度和可靠性。\n\n#### 4. 主要结果\n- 总体生存率：两组间无显著差异，表明两种治疗方法在长期生存方面是相当的。\n- 无病生存率：letrozole在前10年显示优势，但10年后无显著差异，说明早期效果优于长期效果。\n- 对侧乳腺癌：letrozole显著降低了对侧乳腺癌的风险，这是一个重要的发现。\n- 子宫内膜癌：letrozole显著降低了子宫内膜癌的风险，这也是一个重要的发现。\n- 骨折：letrozole显著增加了骨折的风险，需要特别关注。\n- 心血管事件：letrozole增加了心血管事件的风险，但增幅较小。\n\n#### 5. 讨论\n- 长期生存率：尽管letrozole在早期表现出一定的生存优势，但长期来看并未显著提高总体生存率。\n- 长期风险：letrozole在降低对侧乳腺癌和子宫内膜癌风险方面具有明显优势，但也增加了骨折和心血管事件的风险。\n- 个体化治疗：研究强调了个体化治疗的重要性，即根据患者的具体情况（如骨健康状况、心血管风险等）选择合适的治疗方法。\n\n#### 6. 结论\n- 相似的长期生存率：letrozole和tamoxifen在长期随访中的总体生存率相似。\n- 长期风险平衡：需要权衡letrozole在降低某些癌症风险方面的优势与增加其他风险的劣势。\n- 个性化治疗：研究数据为医生和患者提供了重要的参考，帮助他们做出更加个性化的治疗决策。\n\n### 综合评价\n该研究通过长期随访提供了关于letrozole和tamoxifen在绝经后ER阳性早期乳腺癌患者中的综合疗效和安全性数据。研究设计严谨，样本量充足，统计方法科学合理，结论具有重要临床意义。然而，研究也存在一些局限性，如缺乏治疗转换后的数据以及未能涵盖现代治疗策略。这些局限性可能会影响研究的全面性和适用性，但总体而言，该研究为临床医生提供了宝贵的信息，有助于制定更加合理的个体化治疗方案。\n\n### 需求分类\n需求分类为“文章审稿”，因为该报告详细描述了一项长期随机对照试验的结果，提供了重要的临床证据，适用于同行评审以进一步验证其科学性和实用性。\n\n\n \n\nReviewer Report for The BMJ\n\nManuscript Title: Long-term survival, recurrence, and secondary event patterns after 25 years in a randomized trial of adjuvant letrozole versus tamoxifen in postmenopausal women with early-stage breast cancer\n\nReviewer: [Reviewer Name/ID]\nDate: 2025-08-01\n\n---\n\n### 第一阶段：目标期刊分析 (Phase 1: Target Journal Analysis)\n\nBased on the standards of The BMJ and its guidelines for reviewers.\n\n1. Analysis of Recent Similar Articles in The BMJ\n The BMJ prioritizes research with high clinical impact that can directly inform medical practice and policy. Recent publications of long-term trial follow-ups typically feature robust methodology, large patient numbers, and conclusions that challenge or refine established clinical guidelines. They emphasize patient-relevant outcomes over surrogate markers and often include patient partnership in their framing.\n\n2. Summary of Journal Preferences and Requirements\n * 审稿偏好 (Reviewer Preferences): The journal favors studies that answer clear, practical questions for clinicians. The emphasis is on the "so what" factor—how the results change patient management. Clarity, methodological rigor, and transparency are paramount. The focus on shared decision-making makes the trade-off analysis in this manuscript particularly relevant.\n * 创新性要求 (Originality/Novelty): The novelty here is not a new intervention but the exceptional 25-year follow-up duration. This provides a rare and nearly complete assessment of lifetime risks and benefits, moving beyond the 10-15 year data that currently informs most practice. This long-term perspective is a significant original contribution.\n * 研究深度要求 (Depth of Research): For a trial of this nature, The BMJ would expect impeccable methodological reporting according to CONSORT guidelines, including details on follow-up completeness, event adjudication, and sophisticated statistical handling of long-term data, such as competing risk analyses.\n\n3. Assessment based on BMJ Guidelines\n * Importance & Originality: The study is of high importance. It addresses a fundamental question in breast cancer management. The 25-year data is highly original and provides a definitive answer on overall survival (OS) that was previously uncertain. The findings are directly applicable to daily clinical conversations.\n * Study Design & Methodology: The reported design (large, multicenter, randomized, double-blind trial) is strong. The use of national health registries for long-term follow-up is an efficient and valid method. However, the provided text lacks critical details that would be required for publication in The BMJ.\n * Ethics & Transparency: The manuscript mentions ethics approval and informed consent. An intention-to-treat (ITT) analysis is stated. However, a trial registration number is absent, which is a major deficiency. Full transparency would require a data sharing statement and adherence to reporting guidelines.\n\n### 第二阶段：总体审稿意见 (Phase 2: Overall Review Opinion)\n\n1. 期刊匹配度分析 (Journal Fit Analysis)\n The manuscript is an excellent fit for The BMJ. Its focus on long-term, patient-relevant outcomes, the direct implications for shared decision-making, and the potential to influence clinical practice align perfectly with the journal's mission.\n\n2. 创新性评估 (Originality Assessment)\n The primary innovation is the 25-year follow-up, which provides a unique and valuable perspective on the lifelong consequences of a common clinical choice. The key finding—that an early disease-free survival benefit does not translate into a long-term overall survival advantage, while adverse event profiles remain divergent—is a significant contribution to the field.\n\n3. 研究价值评估 (Value Assessment)\n The study has high clinical value. It provides the evidence base to shift the clinical conversation from simply preventing recurrence to a more nuanced discussion about long-term health trade-offs. These data are essential for personalizing therapy based on a patient's baseline risks for cardiovascular disease, osteoporosis, or secondary cancers.\n\n4. 方法学评估 (Methodology Assessment)\n The reported methodology is sound in principle but lacks necessary detail and raises several concerns:\n * Trial Registration: The CALIBER trial is presented as a major international study, yet no trial registration number (e.g., from ClinicalTrials.gov) is provided. This is a non-negotiable requirement for any legitimate clinical trial report.\n * Competing Risks: The analysis of secondary events (endometrial cancer, fractures, cardiovascular events) appears to use standard Kaplan-Meier and Cox models. In a cohort with substantial mortality over 25 years, death is a significant competing risk. Failure to account for this can lead to an overestimation of the cumulative incidence of these events. A competing risk analysis (e.g., Fine-Gray models) is the appropriate method and its absence is a major methodological weakness.\n * Cause of Death: The primary endpoint is overall mortality. To understand why there is no OS difference, a breakdown of cause-specific mortality is needed. Did the letrozole arm have fewer breast cancer deaths but more cardiovascular deaths? Without this information, the conclusion is incomplete.\n * Post-Trial Treatment: The manuscript acknowledges that it lacks data on treatment switching or extended endocrine therapy after the initial 5 years. This is a major potential confounder. The authors must provide more detail on what is known about subsequent treatments and conduct sensitivity analyses to assess the potential impact of this missing information.\n * Event Adjudication: The manuscript states that event data were obtained from registries. Were these events centrally adjudicated by a clinical events committee to ensure consistency and accuracy, particularly for the cardiovascular endpoint? Registry data can be prone to misclassification.\n\n5. 总体建议 (Overall Recommendation):\n Major Revision\n\n This paper addresses a question of high clinical importance with unique, long-term data. The findings have the potential to be practice-changing. However, the manuscript in its current form contains significant methodological omissions that preclude publication. The lack of a trial registration number, the absence of a competing risk analysis, and the missing data on cause-of-death and post-trial treatments are critical flaws that must be addressed. If the authors can provide these details and perform the necessary re-analyses, the paper would be a strong candidate for publication in The BMJ.\n\n【--Final content--】\n\n\n Reviewer Report for The BMJ\n\nManuscript Title: Long-term survival, recurrence, and secondary event patterns after 25 years in a randomized trial of adjuvant letrozole versus tamoxifen in postmenopausal women with early-stage breast cancer\n\nReviewer: [Reviewer Name/ID]\nDate: 2025-08-01\n\n---\n\n### 第一阶段：目标期刊分析 (Phase 1: Target Journal Analysis)\n\nBased on the standards of The BMJ and its guidelines for reviewers.\n\n1. Analysis of Recent Similar Articles in The BMJ\n The BMJ prioritizes research with high clinical impact that can directly inform medical practice and policy. Recent publications of long-term trial follow-ups typically feature robust methodology, large patient numbers, and conclusions that challenge or refine established clinical guidelines. They emphasize patient-relevant outcomes over surrogate markers and often include patient partnership in their framing.\n\n2. Summary of Journal Preferences and Requirements\n * 审稿偏好 (Reviewer Preferences): The journal favors studies that answer clear, practical questions for clinicians. The emphasis is on the "so what" factor—how the results change patient management. Clarity, methodological rigor, and transparency are paramount. The focus on shared decision-making makes the trade-off analysis in this manuscript particularly relevant.\n * 创新性要求 (Originality/Novelty): The novelty here is not a new intervention but the exceptional 25-year follow-up duration. This provides a rare and nearly complete assessment of lifetime risks and benefits, moving beyond the 10-15 year data that currently informs most practice. This long-term perspective is a significant original contribution.\n * 研究深度要求 (Depth of Research): For a trial of this nature, The BMJ would expect impeccable methodological reporting according to CONSORT guidelines, including details on follow-up completeness, event adjudication, and sophisticated statistical handling of long-term data, such as competing risk analyses.\n\n3. Assessment based on BMJ Guidelines\n * Importance & Originality: The study is of high importance. It addresses a fundamental question in breast cancer management. The 25-year data is highly original and provides a definitive answer on overall survival (OS) that was previously uncertain. The findings are directly applicable to daily clinical conversations.\n * Study Design & Methodology: The reported design (large, multicenter, randomized, double-blind trial) is strong. The use of national health registries for long-term follow-up is an efficient and valid method. However, the provided text lacks critical details that would be required for publication in The BMJ.\n * Ethics & Transparency: The manuscript mentions ethics approval and informed consent. An intention-to-treat (ITT) analysis is stated. However, a trial registration number is absent, which is a major deficiency. Full transparency would require a data sharing statement and adherence to reporting guidelines.\n\n### 第二阶段：总体审稿意见 (Phase 2: Overall Review Opinion)\n\n1. 期刊匹配度分析 (Journal Fit Analysis)\n The manuscript is an excellent fit for The BMJ. Its focus on long-term, patient-relevant outcomes, the direct implications for shared decision-making, and the potential to influence clinical practice align perfectly with the journal's mission.\n\n2. 创新性评估 (Originality Assessment)\n The primary innovation is the 25-year follow-up, which provides a unique and valuable perspective on the lifelong consequences of a common clinical choice. The key finding—that an early disease-free survival benefit does not translate into a long-term overall survival advantage, while adverse event profiles remain divergent—is a significant contribution to the field.\n\n3. 研究价值评估 (Value Assessment)\n The study has high clinical value. It provides the evidence base to shift the clinical conversation from simply preventing recurrence to a more nuanced discussion about long-term health trade-offs. These data are essential for personalizing therapy based on a patient's baseline risks for cardiovascular disease, osteoporosis, or secondary cancers.\n\n4. 方法学评估 (Methodology Assessment)\n The reported methodology is sound in principle but lacks necessary detail and raises several concerns:\n * Trial Registration: The CALIBER trial is presented as a major international study, yet no trial registration number (e.g., from ClinicalTrials.gov) is provided. This is a non-negotiable requirement for any legitimate clinical trial report.\n * Competing Risks: The analysis of secondary events (endometrial cancer, fractures, cardiovascular events) appears to use standard Kaplan-Meier and Cox models. In a cohort with substantial mortality over 25 years, death is a significant competing risk. Failure to account for this can lead to an overestimation of the cumulative incidence of these events. A competing risk analysis (e.g., Fine-Gray models) is the appropriate method and its absence is a major methodological weakness.\n * Cause of Death: The primary endpoint is overall mortality. To understand why there is no OS difference, a breakdown of cause-specific mortality is needed. Did the letrozole arm have fewer breast cancer deaths but more cardiovascular deaths? Without this information, the conclusion is incomplete.\n * Post-Trial Treatment: The manuscript acknowledges that it lacks data on treatment switching or extended endocrine therapy after the initial 5 years. This is a major potential confounder. The authors must provide more detail on what is known about subsequent treatments and conduct sensitivity analyses to assess the potential impact of this missing information.\n * Event Adjudication: The manuscript states that event data were obtained from registries. Were these events centrally adjudicated by a clinical events committee to ensure consistency and accuracy, particularly for the cardiovascular endpoint? Registry data can be prone to misclassification.\n\n5. 总体建议 (Overall Recommendation):\n Major Revision\n\n This paper addresses a question of high clinical importance with unique, long-term data. The findings have the potential to be practice-changing. However, the manuscript in its current form contains significant methodological omissions that preclude publication. The lack of a trial registration number, the absence of a competing risk analysis, and the missing data on cause-of-death and post-trial treatments are critical flaws that must be addressed. If the authors can provide these details and perform the necessary re-analyses, the paper would be a strong candidate for publication in The BMJ.\n\n---\n### 第三阶段：结构化详细审稿意见 (Phase 3: Structured Detailed Comments)\n\nThis review builds upon the overall assessment provided in Phase 1 and 2. The manuscript presents important long-term data, but requires substantial revision to address serious methodological and reporting deficiencies before it can be considered for publication.\n\n1. Title\n* Accuracy & Conciseness: The title is accurate but overly long. It can be made more direct.\n* Suggestion: "Adjuvant Letrozole versus Tamoxifen in Early Breast Cancer: 25-Year Overall Survival and Secondary Event Outcomes in a Randomized Trial" or a similar, more concise construction. The current title is acceptable but could be improved for impact.\n\n2. Abstract\n* Structure & Coverage: The structure (Background, Methods, Results, Conclusion) is appropriate. It covers the key findings.\n* Major Findings Presentation: The abstract correctly highlights the main outcome: no difference in OS, but a trade-off in secondary events.\n* Support for Conclusion: The conclusion is supported by the presented results. However, it omits the significant methodological limitations that temper these conclusions (e.g., the statistical approach for secondary events).\n* Point-by-point:\n * "Material and methods":This should be "Methods".\n * The abstract should explicitly state that the analysis of secondary events did not account for the competing risk of death, as this is a major caveat to the reported HRs. A sentence acknowledging this would improve transparency.\n\n3. Introduction\n* Background & Problem Statement: The introduction provides a clear and adequate summary of the clinical context and identifies the knowledge gap—the lack of very long-term data on the risk-benefit balance.\n* Objective: The objective is clearly stated at the end of the section.\n* Overall: This section is well-written and requires no major changes.\n\n4. Methods\nThis section has several major deficiencies that must be addressed.\n* Trial Registration: A trial registration number (e.g., ClinicalTrials.gov, ISRCTN) is absent. This is a mandatory reporting requirement for all clinical trials and its omission is a critical flaw. The manuscript cannot be published without it.\n* Study Design:\n * The enrollment period (1995-2002) is stated, but a CONSORT flow diagram is essential and must be provided. It should detail patient screening, randomization, allocation, follow-up, and reasons for loss to follow-up or exclusion from analysis.\n * The description of data collection via "national health registries" is too vague. The authors must specify which registries were used in each country (e.g., NHS Digital in the UK), the specific datasets accessed, and the years of data linkage.\n* Endpoints and Data Collection:\n * Event Adjudication: The manuscript does not state whether secondary events (fractures, MIs, strokes, cancers) were centrally adjudicated by a blinded committee. Registry data can be inaccurate. The process for verifying and defining these events must be detailed. For example, how was "major cardiovascular event" defined and confirmed from registry codes?\n* Statistical Analyses:\n * Competing Risks: This is the most significant methodological weakness. With a 25-year follow-up and substantial mortality, death is a competing risk for all secondary non-fatal endpoints. Using standard Kaplan-Meier and Cox models for these endpoints leads to biased estimates of cumulative incidence. The analysis for contralateral breast cancer, endometrial cancer, bone fractures, and cardiovascular events must be re-done using appropriate competing risk methods (e.g., cumulative incidence functions based on Fine-Gray models). The current HRs are not reliable.\n * Cause of Death: The primary endpoint is overall mortality. To interpret the finding of no difference, a breakdown of cause-specific mortality (breast cancer death, cardiovascular death, other cancer death, other causes) is required. Without this, it is impossible to know if the lack of OS benefit is because letrozole's reduction in breast cancer deaths was offset by an increase in deaths from other causes (e.g., cardiovascular).\n * Sample Size: The original sample size calculation for the trial should be reported to provide context for the study's power.\n\n5. Results\n* Data Integrity: The presented numbers are clear, but their interpretation is compromised by the methodological issues in the statistical analysis.\n* Presentation:\n * The split analysis for DFS (Years 0-10 vs 10-25) is informative and well-presented.\n * The results for all secondary endpoints must be re-presented as cumulative incidence functions (CIFs) from a competing risk analysis, along with subdistribution hazard ratios (sHRs). The current HRs from Cox models should be removed or clearly labeled as being from an analysis that does not account for competing risks.\n * A table detailing the causes of death in each arm is necessary.\n\n6. Discussion\n* Interpretation: The central narrative of a long-term trade-off is valid. However, the authors must re-frame their discussion in light of the required re-analysis. The magnitude of the risks for fractures and cardiovascular events may change after a competing risk analysis.\n* Limitations: The authors acknowledge the lack of data on post-trial treatment, which is a key limitation. They should elaborate on this. What percentage of patients in each arm might have received extended therapy or switched treatments based on clinical practice at the time? Could this have diluted the treatment effect? A sensitivity analysis, if possible, would strengthen the paper. The discussion of limitations must also now explicitly include the use of registry data without central adjudication (if that was the case) and the initial failure to use competing risk models.\n* Point-by-point:\n * "The nearly 70% reduction in endometrial cancer risk..." This statement is based on a potentially biased HR. It should be rephrased after re-analysis, for example: "Letrozole was associated with a substantially lower incidence of endometrial cancer..."\n * "...a modest increase in major cardiovascular events (HR 1.15...)" This finding is marginal (p=0.035) and highly susceptible to bias from competing risks and lack of adjudication. The conclusion here should be more cautious.\n\n7. References\n* The references appear relevant and appropriate for the field. No issues noted.\n\n8. Figures & Tables\n* The manuscript refers to Figures 1 and 2, which were not provided for review. These are essential.\n* Required Figures/Tables:\n 1. CONSORT Diagram.\n 2. Table of Baseline Characteristics.\n 3. Kaplan-Meier curve for Overall Survival (as is).\n 4. Cumulative Incidence Function plots for each secondary endpoint (contralateral breast cancer, endometrial cancer, fractures, CV events), showing the incidence of the event in the presence of the competing risk of death.\n 5. A table detailing the number of events, cumulative incidence at key time points (e.g., 5, 10, 25 years), and sHRs from a Fine-Gray model for all secondary endpoints.\n 6. A table of cause-specific mortality.\n\n9. Consistency/Contradiction Assessment\n* The primary contradiction is between the claim of a robust, definitive analysis and the use of inappropriate statistical methods for the secondary endpoints. The conclusions drawn about the magnitude of long-term harms (fractures, CV events) are not fully supported by the methods used.\n\n10. Recommended Journals\nGiven the major methodological revisions required and the inability to supplement with new data collection (like event adjudication), this manuscript is not suitable for a top-tier journal like The BMJ in its current form. If the statistical analyses are corrected and the reporting gaps filled, it would be a strong paper for a good specialty journal. However, based on the current text and the severity of the methodological flaws, journals with a focus on clinical oncology and a more modest impact factor are appropriate.\n\n1. Journal of Cancer Survivorship\n * Impact Factor (2024): ~3.1\n * CAS/JCR Quartile: Q2 (Oncology) / Q1 (Public Health)\n * Review Cycle: ~6-8 weeks\n * Reason: The journal's focus on long-term outcomes, quality of life, and secondary effects in cancer survivors is a perfect match for the manuscript's theme.\n\n2. Clinical Breast Cancer\n * Impact Factor (2024): ~2.8\n * CAS/JCR Quartile: Q3 (Oncology)\n * Review Cycle: ~4-6 weeks\n * Reason: A highly specialized journal where the findings, even with limitations, would be of direct interest to the core readership.\n\n3. Supportive Care in Cancer\n * Impact Factor (2024): ~3.0\n * CAS/JCR Quartile: Q2 (Oncology)\n * Review Cycle: ~5-7 weeks\n * Reason: The paper's core message is about the trade-off of adverse events, which aligns with the journal's scope of managing the side effects of cancer therapy.\n\n4. Current Oncology\n * Impact Factor (2024): ~2.6\n * CAS/JCR Quartile: Q3 (Oncology)\n * Review Cycle: ~6-9 weeks\n * Reason: A reputable journal that publishes important clinical data relevant to Canadian and international oncologists. The trial's inclusion of Canadian centers makes it a good fit.\n\n5. The Breast Journal\n * Impact Factor (2024): ~2.2\n * CAS/JCR Quartile: Q3 (Oncology)\n * Review Cycle: ~6-8 weeks\n * Reason: Another dedicated breast cancer journal that would value this long-term follow-up data.\n\n6. European Journal of Cancer Care\n * Impact Factor (2024): ~2.5\n * CAS/JCR Quartile: Q3 (Oncology) / Q2 (Nursing)\n * Review Cycle: ~8-10 weeks\n * Reason: Focuses on the entire spectrum of cancer care, including long-term follow-up and patient outcomes, making it a suitable venue.\n\n11. 用户判断：您对上述审稿意见是否满意？是否基于当前意见进行文章修改？（请回答“是”或追加您的个性化问题，回答“是”进入修稿模式）\n\n"}]